September, 2022.- The early detection of metastasis in patients with prostate cancer is the goal of ProstaMets, a prognostic test that analyzes the progression of this tumor through the detection of genetic markers. This technology –which has been awarded and highlighted in the R&D ecosystem– is a development of Environ, a biotechnological startup born in the Pontifical Catholic University of Chile.
The company has just signed a collaboration agreement with the Innovation and Tech Transfer departament of the Millennium Institute Foundational Research on Data (IMFD), which seeks to apply the experience in data science and artificial intelligence of this unit into the biotech field. The test detects the presence of genes present in the microenvironment of the tumor and these data are taken by an algorithm to analyze and measure the progression of metastasis.
“We hope to contribute to the automation of this process, through the application of explainability techniques that allow us to visualize the process from when the algorithm receives the data until it produces a forecast,” says Jazmine Maldonado, CEO of Innovation IMFD. In this way, not only the automated analysis system is assessed, but also it will be possible to know the incidence of every gene in each forecast, and so to enrich the research that Environ carries out.